BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

977 related articles for article (PubMed ID: 16276514)

  • 1. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.
    Dash S; Prabhu R; Hazari S; Bastian F; Garry R; Zou W; Haque S; Joshi V; Regenstein FG; Thung SN
    Liver Int; 2005 Jun; 25(3):580-94. PubMed ID: 15910496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus].
    Cooreman MP; Stadhouders P
    Orv Hetil; 1997 Jun; 138(22 Suppl 1):1476-82. PubMed ID: 9221377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus (HCV)--a review molecular biology of the virus, immunodiagnostics, genomic heterogeneity and the role of virus in hepatocellular carcinoma.
    Poduri CD
    Indian J Exp Biol; 2003 Jun; 41(6):549-62. PubMed ID: 15266899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.
    Zhu H; Dong H; Eksioglu E; Hemming A; Cao M; Crawford JM; Nelson DR; Liu C
    Gastroenterology; 2007 Nov; 133(5):1649-59. PubMed ID: 17983809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present and future therapy for hepatitis C virus.
    Cornberg M; Deterding K; Manns MP
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):781-93. PubMed ID: 17140355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C--clinical profile.
    Bhandari B; Pal A
    J Indian Med Assoc; 2007 Aug; 105(8):453-4, 456, 465. PubMed ID: 18236909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
    Masuzaki R; Yoshida H; Omata M
    Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.